Trial Profile
An Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Patients With Mucopolysaccharidosis I Who Were Previously Enrolled in Studies With AGT-181
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Valanafusp alfa (Primary)
- Indications Mucopolysaccharidosis I
- Focus Adverse reactions
- Sponsors ArmaGen Technologies
- 16 Sep 2018 Status changed from recruiting to completed.
- 08 Mar 2017 New trial record